Sandoz, Others Prevail In California Patent Dispute Over Biosimilar Treatment

(December 20, 2017, 1:47 PM EST) -- SAN FRANCISCO — A California federal judge on Dec. 19 granted four defendants summary judgment of noninfringement with regard to a patent covering the neutropenia treatments Neupogen and Neulasta (Amgen Inc....
To view the full article, register now.